UroCCR database

Service de Chirurgie Urologique et Transplantation rénale Hôpital Pellegrin - CHU de Bordeaux Place Amélie Raba Léon 33076 Bordeaux Cedex



UroCCR is the French research network for kidney cancer, funded by the French National Cancer Institute as part of the call for projects for clinical and biological databases (BCB).

The network currently comprises 15 multidisciplinary clinical teams all around the country, a methodological unit and several partners such as 4 Learned Societies (AFU, GETUG, SIGU and the French club of Uropathology) and the French Cancer Registries (FRANCIM) (www.uroccr.fr). The national coordinator of the UroCCR network is Jean-Christophe BERNHARD, MD PhD (Bordeaux University Hospital).

This is a medical and scientific national network dedicated to therapeutic management and applied research on kidney cancer. Using a web-shared clinical and biological database in addition to a multicenter collection of biological samples our objective is to ease the development of observational, interventional, and translational clinical research projects. The existing partnerships between UroCCR and the French network of cancer registries (FRANCIM) along with various learned societies specialized in the involved areas reinforce the network’s scientific and epidemiologic scope.

This multidisciplinary and multicenter database model represents a major asset for performing epidemiological, observational and translational researches at a national level. The common interface and the direct link with local tumor banks allow an easy and centralized access to biological resources. Based on a strong multidisciplinary clinical rooting and an ongoing prospective patients’ inclusion it also offers to scientists an opportunity to access a wide panel of kidney cancer patients for prospective projects.


  1. Pierquet G, Zongo D, Robert G, Pasticier G, Maurice-Tison S, Bensadoun H, Ballanger P, Rouget B, Ferriere JM, Bernhard JC. Partial nephrectomy on solitary kidney: Renal function outcome and predictive factors of impairment. Prog Urol. 2016 Jan;26(1):34-40. French.
  2. Bernhard JC, Isotani S, Matsugasumi T, et al. Personalized 3D printed model of kidney and tumor anatomy: a useful tool for patient education. World J Urol. 2015 Jul 11.
  3. Bernhard JC, Bigot P, Pignot G, et al; NEPHRON Study Group. The accuracy of renal tumor biopsy: analysis from a national prospective study. World J Urol. 2015 Aug;33(8):1205-11.
  4. Bigot P, Lebdai S, Ravaud A, Azzouzi AR, Ferrière JM, Patard JJ, Bernhard JC. The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol. 2013 Dec;31(6):1383-8.
  5. Douard A, Pasticier G, Deminière C, Wallerand H, Ferrière JM, Bernhard JC. Primary angiosarcoma of the kidney: case report and literature review. Prog Urol. 2012 Jun;22(7):438-41. French.


  1. Bigot P, Pignot G, Bernhard JC, Patard JJ. Neoadjuvant targeted therapies in renal cell carcinoma. Prog Urol. 2016 Jan 15. pii: S1166-7087(15)00757-5. French.
  2. Bigot P, Bernhard JC, Gill IS, et al; members of the Kidney Cancer group of the CCAFU. The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World J Urol. 2015 Jul 7.
  3. Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, et al. Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features. Urol Oncol. 2015 Aug;33(8):339.e9-15.
  4. Satkunasivam R, Tsai S, Syan S, Bernhard JC, et al. Robotic unclamped "minimal-margin" partial nephrectomy: ongoing refinement of the anatomic zero-ischemia concept. Eur Urol. 2015 Oct;68(4):705-12.
  5. Chen F, Huhdanpaa H, Desai B, Hwang D, Cen S, Sherrod A, Bernhard JC, et al. Whole lesion quantitative CT evaluation of renal cell carcinoma: differentiation of clear cell from papillary renal cell carcinoma. Springerplus. 2015 Feb 10;4:66.